Inactive Instrument

ADL Bionatur Solutions, S.A. Stock price BME

Equities

Biotechnology & Medical Research

Sales 2021 3.28M 3.54M Sales 2022 2.96M 3.19M Capitalization 12.42M 13.4M
Net income 2021 -3M -3.24M Net income 2022 -1M -1.08M EV / Sales 2021 8.37 x
Net Debt 2021 6.53M 7.05M Net Debt 2022 7.45M 8.03M EV / Sales 2022 6.72 x
P/E ratio 2021
-6.95 x
P/E ratio 2022
-6.41 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 51.48%
More Fundamentals * Assessed data
Dynamic Chart
Biotechnology Assets, S.A. Auditor Raises 'Going Concern' Doubt CI
Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Biotechnology Assets, S.A. Auditor Raises 'Going Concern' Doubt CI
Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
ADL Bionatur Solutions, S.A. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
ADL Bionatur Solutions, S.A. announced that it has received ?12 million in funding from Kartesia Advisor LLP CI
Adl Bionatur Solutions, S.A. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' Doubt CI
ADL Bionatur Solutions, S.A. announced that it expects to receive €5 million in funding CI
ADL Bionatur Solutions, S.A. announced that it has received €12 million in funding from Kartesia Advisor LLP CI
Kartesia Advisor LLP acquired 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. and Black Toro Capital LLP. CI
ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' Doubt CI
ADL Bionatur Solutions Wins New Fermentation Client With Contract Revenues of EUR 20 Million CI
ADL Bionatur Solutions Announces Revenue Results for the Third Quarter and Nine Months of 2019; Confirms Revenue Guidance for the Full Year of 2019 CI
ADL Bionatur Solutions Announces Earnings Results for the First Six Months of 2019; Provides Guidance for the Full Year 2019 CI
More news
Managers TitleAgeSince
Director of Finance/CFO 60 19-10-31
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer - 06-12-31
Members of the board TitleAgeSince
Chairman - -
Director/Board Member - -
Director/Board Member 68 -
More insiders
Biotechnology Assets SA, formerly known as ADL Bionatur Solutions SA, is a Spain-based biotech company. The Firm's main activities are: Research, development and production of biotechnological solutions aimed at improving the health and welfare of people and animals; Development, acquisition, transfer and exploitation of industrial and intellectual property rights; Distribution, marketing, export and import of the previously mentioned products. The Company, through its subsidiaries, is also present in Luxembourg, Hong Kong and USA.
More about the company
  1. Stock
  2. Equities
  3. Stock Biotechnology Assets, S.A.
  4. Stock ADL Bionatur Solutions, S.A. - BME